中国P站

Tumor pathology; Multi-omics; Artificial Intelligence (AI); Digital pathology; Liquid biopsy; Molecular pathology; Biomarkers; Tumor microenvironment; Neuropathology; Cancer staging; Precision oncology; Personalized medicine

Introduction

Integrated multi-omics approaches are crucial for understanding aggressive cancers like pancreatic ductal adenocarcinoma (PDAC), combining genomic, transcriptomic, and proteomic data. This method helps uncover novel molecular mechanisms driving tumor development, identifying potential therapeutic targets, and highlighting its power in dissecting complex cancer biology[1].

Immunohistochemistry (IHC) is a foundational tool in tumor pathology, supporting precise diagnosis, classification, and prognostic assessment. This review details IHC's expanding role, from identifying specific tumor markers to its use in personalized medicine, and explores advancements like multiplex IHC and integration with digital pathology for comprehensive tumor characterization[2].

Artificial Intelligence (AI) is transforming tumor diagnosis and prognosis through its integration with digital pathology. AI algorithms analyze whole-slide images, offering quantitative, reproducible assessments that enhance human pathologist capabilities. This includes AI's role in tumor detection, classification, grading, and predicting therapeutic response, significantly improving efficiency and accuracy in routine clinical practice[3].

Liquid biopsy is an evolving field in tumor pathology, providing a non-invasive alternative to traditional tissue biopsies. It detects circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers in blood. This offers significant promise for early cancer detection, monitoring disease progression and treatment response, and assessing minimal residual disease, thereby guiding personalized patient management strategies[4].

Molecular pathology has advanced cancer diagnostics beyond morphology, offering critical insights into tumors' genetic and molecular foundations. Identifying specific gene mutations, fusions, and expression profiles guides targeted therapies and informs prognosis. Techniques like next-generation sequencing and FISH are essential for accurate tumor classification and personalized treatment approaches in oncology[5].

The tumor microenvironment (TME) is a complex ecosystem profoundly influencing cancer progression, metastasis, and therapy response. Pathological perspectives on the TME detail how interactions between tumor cells, immune cells, stromal cells, and the extracellular matrix contribute to tumor heterogeneity and therapeutic resistance. Understanding these interactions is critical for developing novel strategies targeting TME components[6].

Identifying robust prognostic and predictive biomarkers is central to precision oncology. Emerging biomarkers from tissue, blood, and imaging provide insights into disease aggressiveness, recurrence risk, and treatment response likelihood. Integrating these into pathological assessment improves patient stratification and guides individualized therapeutic decisions[7].

Neuropathology of brain tumors is rapidly evolving towards an integrated diagnostic approach, combining histological features with molecular profiling. Molecular markers, such as IDH mutations and 1p/19q co-deletion, are essential for accurate glioma classification and grading per WHO guidelines. This shift provides comprehensive molecular and morphological assessments crucial for patient management and targeted therapies[8].

Understanding the unique pathological features of tumors in hereditary cancer syndromes is vital for accurate diagnosis and patient care. This includes characteristic histological and molecular findings associated with syndromes like Lynch, hereditary breast and ovarian cancer, and Li-Fraumeni. Recognizing these patterns guides genetic testing, surveillance, and tailored therapeutic interventions for affected individuals and their families[9].

Tumor staging is a critical component of cancer management, directly influencing treatment decisions and prognostic predictions. Updates in pathological staging systems, such as the TNM classification, impact clinical practice. Pathologists accurately assess tumor size, nodal involvement, and distant metastasis, integrating these with molecular data to provide comprehensive information for personalized treatment planning and improved patient outcomes[10].

Description

The landscape of cancer diagnostics has profoundly evolved, moving beyond mere morphological assessment to embrace advanced molecular and integrated approaches. Multi-omics strategies, which combine genomic, transcriptomic, and proteomic data, are proving instrumental in deciphering the complex biology of aggressive cancers like pancreatic ductal adenocarcinoma, facilitating the identification of novel therapeutic targets [1]. Concurrently, molecular pathology has emerged as a cornerstone, providing critical insights into the genetic and molecular underpinnings of tumors. Techniques such as next-generation sequencing and FISH are now essential for pinpointing specific gene mutations and expression profiles, which in turn guide targeted therapies and refine prognosis, moving cancer management towards truly personalized approaches [5]. Even traditional methods like Immunohistochemistry (IHC) continue to play a vital role, with ongoing advancements in antibody development and automation. IHC remains crucial for precise diagnosis, tumor classification, and prognostic assessment, with future directions focusing on multiplex IHC and its integration into digital pathology workflows for more comprehensive tumor characterization [2].

A significant leap in tumor pathology comes from the integration of Artificial Intelligence (AI) with digital pathology. AI algorithms are revolutionizing how tumors are diagnosed and prognosticated by meticulously analyzing whole-slide images. This technology provides quantitative and highly reproducible assessments, effectively augmenting the capabilities of human pathologists. AI plays a multifaceted role, including enhancing tumor detection, aiding in precise classification and grading, and even predicting responses to various therapies. The implementation of AI promises to substantially improve both the efficiency and accuracy of routine clinical practice, ultimately leading to better patient care and outcomes [3].

Non-invasive diagnostic tools are gaining prominence, with liquid biopsy representing a rapidly evolving and highly promising field in tumor pathology. This technique offers a less intrusive alternative to traditional tissue biopsies by detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other crucial biomarkers directly from blood samples. Liquid biopsy holds immense potential for the early detection of cancer, real-time monitoring of disease progression, assessing treatment efficacy, and identifying minimal residual disease, all of which are instrumental in informing personalized patient management strategies [4]. Building on this, the identification and validation of robust prognostic and predictive biomarkers are paramount for advancing precision oncology. These emerging biomarkers, sourced from tissues, blood, and imaging, offer invaluable insights into disease aggressiveness, recurrence risk, and the likelihood of response to specific treatments. Their integration into routine pathological assessment allows for improved patient stratification and facilitates more individualized therapeutic decisions [7].

A deeper understanding of cancer biology now includes the complex ecosystem of the tumor microenvironment (TME). The TME, composed of various cells and extracellular components, profoundly influences cancer progression, metastasis, and its resistance to therapies. Pathological insights into TME interactions—between tumor cells, immune cells, stromal cells, and the extracellular matrix—are critical for explaining tumor heterogeneity and developing novel therapeutic strategies specifically targeting these components [6]. Furthermore, recognizing the unique pathological features associated with hereditary cancer syndromes is essential for precise diagnosis and effective patient management. Comprehensive overviews of characteristic histological and molecular findings in syndromes like Lynch, hereditary breast and ovarian cancer, and Li-Fraumeni guide crucial genetic testing, surveillance protocols, and tailored therapeutic interventions for affected individuals and their families [9].

In specialized areas like neuropathology, diagnostics are rapidly moving towards an integrated approach that merges classic histological features with comprehensive molecular profiling. For brain tumors, particularly gliomas, molecular markers such as IDH mutations and 1p/19q co-deletion are now indispensable for accurate classification and grading, adhering to updated WHO guidelines. This signifies a fundamental shift from solely morphology-based diagnoses to a more holistic molecular and morphological assessment, which is vital for effective patient management and the application of targeted therapies [8]. Additionally, tumor staging remains a cornerstone of cancer management, directly impacting treatment decisions and prognostic predictions. Recent updates and refinements in pathological staging systems, such as the TNM classification, underscore the pathologist's pivotal role. Accurate assessment of tumor size, nodal involvement, and distant metastasis, combined with molecular data, provides comprehensive information crucial for personalized treatment planning and ultimately improving patient outcomes [10].

Conclusion

Modern tumor pathology is undergoing a significant transformation, moving beyond traditional morphological assessments to embrace advanced molecular and digital techniques. This shift is crucial for precision diagnostics, personalized therapy, and improved patient outcomes. Key advancements include integrated multi-omics approaches, which combine genomic, transcriptomic, and proteomic data to dissect complex cancers like pancreatic ductal adenocarcinoma, uncovering novel mechanisms and therapeutic targets. Immunohistochemistry (IHC) remains foundational, evolving with new antibody developments and automation, and is poised for integration with digital pathology for more comprehensive tumor characterization. Artificial Intelligence (AI) is revolutionizing digital pathology, offering quantitative and reproducible analyses of whole-slide images, enhancing tumor detection, classification, and grading, thereby boosting efficiency and accuracy in clinical practice. Liquid biopsy presents a non-invasive alternative for early detection, monitoring disease progression, and assessing treatment response through circulating biomarkers like ctDNA and CTCs. Molecular pathology, with techniques such as next-generation sequencing, offers crucial insights into genetic mutations and expression profiles, guiding targeted therapies. The tumor microenvironment (TME) is now recognized as a critical factor influencing cancer progression and therapeutic resistance, necessitating targeted strategies. Furthermore, the identification of prognostic and predictive biomarkers from various sources improves patient stratification. Neuropathology integrates histological features with molecular profiling for accurate brain tumor classification. Understanding hereditary cancer syndromes pathology guides genetic testing and tailored interventions. Finally, refined tumor staging systems, like TNM, remain vital for cancer management, integrating pathological and molecular data for personalized treatment planning.

References

1. Jian L, Yang W, Lin Z (2023) .Cancers (Basel) 15:3662.

   , ,

2. Shubham S, Pratyush P, Ankit B (2022) .Cells 11:2085.

   , ,

3. Hao C, Lijun W, Shanshan X (2024) .Cancers (Basel) 16:341.

   , ,

4. Yong K, Seung L, Joon P (2023) .J Clin Med 12:4048.

   , ,

5. Adam CJ, Brenda LS, James DW (2021) .Mod Pathol 34:110-125.

   , ,

6. Yan Z, Hua L, Zhen W (2022) .Cancers (Basel) 14:4578.

   , ,

7. Ritu G, Sandeep S, Anil K (2023) .J Transl Med 21:387.

   , ,

8. Thomas J, Michael D, Robert M (2024) .J Clin Neurosci 110:108-117.

   , ,

9. Charis E, Min-Han T, Hong L (2020) .Cancers (Basel) 12:2828.

   , ,

10. Yusuke A, Takashi I, Masaaki O (2019) .Cancers (Basel) 11:1530.

    , ,